Integra Lifesciences Holdings Corp (IART) 45.30 $IART
Integra LifeSciences to Host Its First Quarter 2014 Earnings Results Conference Call on May 1, 2014
GlobeNewswire - Fri Apr 11, 8:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its first quarter 2014 financial results on Thursday, May 1, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
Integra LifeSciences to Host Investor Meeting on May 6, 2014
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will host an Investor Meeting on Tuesday, May 6, 2014, at 9:00AM ET, in New York City. The meeting will feature presentations by Integra's senior management team focused on the Company's strategy.
The Zacks Analyst Blog Highlights: Alcoa, J.P. Morgan, Wells Fargo, Integra LifeSciences Holdings and Covidien
PR Newswire - Tue Apr 08, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Alcoa (NYSE:AA-Free Report), J.P. Morgan (NYSE:JPM-Free Report), Wells Fargo (NYSE:WFC-Free Report), Integra LifeSciences Holdings Corporation (Nasdaq:IART-Free Report) and Covidien plc (NYSE:COV-Free Report).
Integra LifeSciences Appoints Mark Augusti as Corporate Vice President, President, Orthopedics and Tissue Technologies
GlobeNewswire - Mon Apr 07, 3:36PM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Mark Augusti has joined Integra as CVP, President, Orthopedics and Tissue Technologies. Mr. Augusti will be responsible for the management of our Spine and Extremities divisions, including strategic direction, portfolio management and evaluation of corporate development opportunities.
Surgical Equipment Market 2013-2019: Surgical Sutures and Staples, Surgical Handheld Instruments, and Electrosurgical Devices
M2 - Mon Apr 07, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prvjh4/surgical) has announced the addition of the "Surgical Equipment Market 2013-2019: Surgical Sutures and Staples, Surgical Handheld Instruments, and Electrosurgical Devices" report to their offering. This report on surgical equipment market studies the current scenario as well as the future market potential for various surgical equipment globally. The market for surgical equipment has been segmented into three major product types, namely: - Surgical Sutures and Staples - Surgical Handheld Instruments - Electrosurgical Devices The market for this equipment has been extensively analyzed on the basis of various factors such as their application in various surgical procedures, worldwide availability, major manufacturers and technological developments. The surgical sutures and staples market has been further segmented into surgical sutures and surgical staples, while the market for surgical handheld instruments has been segmented into scalpels, forceps, retractors and scissors. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2010 to 2019, considering 2010 and 2011 as historical data and 2012 as the base year. This report on surgical equipment market also provides the compounded annual growth rate (CAGR %) for each segment of the market for the forecast period 2013 to 2019. The report also provides a section on the competitive landscape of the surgical equipment market, wherein the market share analysis of leading players, in terms of percentage share in 2012, has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. Surgical Equipment Market, by Product Type - Surgical Sutures and Staples - - Surgical Sutures - - Surgical Staples - Surgical Handheld Instruments - - Scalpels - - Forceps - - Retractors - - Scissors - Electrosurgical Devices Key Topics Covered: - Preface - Executive Summary - Market Overview - Global Surgical Equipment Market Revenue, by Product Type, 2010 - 2019 (USD Million) - Global Surgical Equipment Market Revenue, by Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Recommendations - Company Profiles - Aspen Surgical Products, Inc. - B. Braun MelsungenAG - CONMED Corporation - CareFusion Corporation - Covidien plc - ERBE Elektromedizin GmbH - Ethicon, Inc. - Integra LifeSciences Holdings Corporation - KLS Martin LP - Medicon eG - Stryker Corporation For more information visit http://www.researchandmarkets.com/research/prvjh4/surgical
Integra LifeSciences Announces Camino(R) Flex Ventricular Catheter Receives FDA Clearance for Use With MRI Scans
GlobeNewswire - Fri Apr 04, 7:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that the Camino(R) Flex Ventricular Catheter has received clearance from the United States Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI). The Camino Flex Ventricular Catheter is an advanced, tunneled ventricular catheter that is MR conditional at 1.5 and 3.0 T, with a sensor designed to measure directly at the source, and is used with Integra's next-generation Camino(R) Monitor, which debuted in 2013. Integra is a leading provider of advanced intracranial pressure monitoring (ICP) systems. Over 800 centers in the United States use the Camino platform for conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and stroke.
Integra LifeSciences Introduces Wound Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:34PM CDT
New Jersey-based Integra LifeSciences Holding Corporation (IART) has expanded its skin and wound product line with the launch of Integra Wound Matrix (Thin).
Integra LifeSciences Launches Integra(R) Wound Matrix (Thin)
GlobeNewswire - Tue Mar 25, 7:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of Integra Wound Matrix (Thin). Integra Wound Matrix (Thin) has received 510(k) clearance from the United States Food and Drug Administration (FDA) and expects to begin a full market release in the United States in April 2014. Integra's newest skin product will be featured at the American Burn Association Annual Meeting, March 25 - 28, 2014, in Boston, Massachusetts.
Use Options For A Chance To Buy IART At A 28% Discount
at The Street - Fri Mar 21, 10:57AM CDT
Looking back to 135 days ago, Integra LifeSciences Holdings Corp priced a 3,500,000 share secondary stock offering at $40.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go...
First Laminoplasty Implant at Integra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 5:00PM CDT
Integra LifeSciences announced the first human implantation of its Laminoplasty System in the U.S.
Integra LifeSciences Announces First Implantation of Integra(R) Laminoplasty System
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the first implantation of its Integra(R) Laminoplasty System, in the United States. The system, which is used to treat patients with ossification of the posterior longitudinal ligament, cervical myelopathy and degenerative spinal canal stenosis, was implanted by Douglas Orndorff, M.D., Orthopaedic Spine Surgeon at the Mercy Medical Center in Durango, Colorado.
Integra LifeSciences to Participate in the Barclays Global Healthcare Conference in March
GlobeNewswire - Mon Mar 03, 3:15PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conference next month:
Integra LifeSciences Receives FDA Clearance for Integra(R) Titanium Bone Wedges
GlobeNewswire - Thu Feb 27, 8:51AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the introduction of the Integra Titanium Bone Wedges, designed for internal fixation for bone fractures or osteotomies in the foot and ankle. The system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and will be featured at the American College of Foot and Ankle Surgeons (ACFAS) 72 Annual Scientific Conference, February 27 - March 2, 2014, in Orlando, Florida.
Integra LifeSciences Appoints Kenneth Burhop, Ph.D., as Corporate Vice President and Chief Scientific Officer
GlobeNewswire - Tue Feb 25, 7:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Kenneth Burhop has joined Integra as Corporate Vice President, Chief Scientific Officer. Dr. Burhop will be responsible for setting Integra's strategic scientific vision and roadmap, and will lead the Company's portfolio prioritization and management, and the scientific evaluation of corporate development and new product opportunities.
Integra LifeSciences Reports Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Feb 25, 5:00AM CST
Increases Fourth Quarter Revenues 3% to $221 Million
Integra LifeSciences to Participate in the 2014 Citi Global and RBC Capital Markets Healthcare Conferences in February
GlobeNewswire - Mon Feb 10, 8:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conferences next month:
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Integra LifeSciences Completes Acquisition of DuraSeal Product Lines From Covidien
GlobeNewswire - Wed Jan 15, 3:05PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed the acquisition of DuraSeal product lines from Covidien. Now, together with our DuraGen(R) family of grafts, Integra offers surgeons the largest portfolio of dural repair solutions.
Integra LifeSciences to Host Its Fourth Quarter 2013 Earnings Results Conference Call on February 25, 2014
GlobeNewswire - Mon Jan 13, 8:03AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its fourth quarter 2013 financial results on Tuesday, February 25, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
Integra LifeSciences to Host Its First Quarter 2014 Earnings Results Conference Call on May 1, 2014
GlobeNewswire - Fri Apr 11, 8:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its first quarter 2014 financial results on Thursday, May 1, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
Integra LifeSciences to Host Investor Meeting on May 6, 2014
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will host an Investor Meeting on Tuesday, May 6, 2014, at 9:00AM ET, in New York City. The meeting will feature presentations by Integra's senior management team focused on the Company's strategy.
The Zacks Analyst Blog Highlights: Alcoa, J.P. Morgan, Wells Fargo, Integra LifeSciences Holdings and Covidien
PR Newswire - Tue Apr 08, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Alcoa (NYSE:AA-Free Report), J.P. Morgan (NYSE:JPM-Free Report), Wells Fargo (NYSE:WFC-Free Report), Integra LifeSciences Holdings Corporation (Nasdaq:IART-Free Report) and Covidien plc (NYSE:COV-Free Report).
Integra LifeSciences Appoints Mark Augusti as Corporate Vice President, President, Orthopedics and Tissue Technologies
GlobeNewswire - Mon Apr 07, 3:36PM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Mark Augusti has joined Integra as CVP, President, Orthopedics and Tissue Technologies. Mr. Augusti will be responsible for the management of our Spine and Extremities divisions, including strategic direction, portfolio management and evaluation of corporate development opportunities.
Surgical Equipment Market 2013-2019: Surgical Sutures and Staples, Surgical Handheld Instruments, and Electrosurgical Devices
M2 - Mon Apr 07, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prvjh4/surgical) has announced the addition of the "Surgical Equipment Market 2013-2019: Surgical Sutures and Staples, Surgical Handheld Instruments, and Electrosurgical Devices" report to their offering. This report on surgical equipment market studies the current scenario as well as the future market potential for various surgical equipment globally. The market for surgical equipment has been segmented into three major product types, namely: - Surgical Sutures and Staples - Surgical Handheld Instruments - Electrosurgical Devices The market for this equipment has been extensively analyzed on the basis of various factors such as their application in various surgical procedures, worldwide availability, major manufacturers and technological developments. The surgical sutures and staples market has been further segmented into surgical sutures and surgical staples, while the market for surgical handheld instruments has been segmented into scalpels, forceps, retractors and scissors. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2010 to 2019, considering 2010 and 2011 as historical data and 2012 as the base year. This report on surgical equipment market also provides the compounded annual growth rate (CAGR %) for each segment of the market for the forecast period 2013 to 2019. The report also provides a section on the competitive landscape of the surgical equipment market, wherein the market share analysis of leading players, in terms of percentage share in 2012, has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. Surgical Equipment Market, by Product Type - Surgical Sutures and Staples - - Surgical Sutures - - Surgical Staples - Surgical Handheld Instruments - - Scalpels - - Forceps - - Retractors - - Scissors - Electrosurgical Devices Key Topics Covered: - Preface - Executive Summary - Market Overview - Global Surgical Equipment Market Revenue, by Product Type, 2010 - 2019 (USD Million) - Global Surgical Equipment Market Revenue, by Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Recommendations - Company Profiles - Aspen Surgical Products, Inc. - B. Braun MelsungenAG - CONMED Corporation - CareFusion Corporation - Covidien plc - ERBE Elektromedizin GmbH - Ethicon, Inc. - Integra LifeSciences Holdings Corporation - KLS Martin LP - Medicon eG - Stryker Corporation For more information visit http://www.researchandmarkets.com/research/prvjh4/surgical
Integra LifeSciences Announces Camino(R) Flex Ventricular Catheter Receives FDA Clearance for Use With MRI Scans
GlobeNewswire - Fri Apr 04, 7:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that the Camino(R) Flex Ventricular Catheter has received clearance from the United States Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI). The Camino Flex Ventricular Catheter is an advanced, tunneled ventricular catheter that is MR conditional at 1.5 and 3.0 T, with a sensor designed to measure directly at the source, and is used with Integra's next-generation Camino(R) Monitor, which debuted in 2013. Integra is a leading provider of advanced intracranial pressure monitoring (ICP) systems. Over 800 centers in the United States use the Camino platform for conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and stroke.
Integra LifeSciences Introduces Wound Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:34PM CDT
New Jersey-based Integra LifeSciences Holding Corporation (IART) has expanded its skin and wound product line with the launch of Integra Wound Matrix (Thin).
Integra LifeSciences Launches Integra(R) Wound Matrix (Thin)
GlobeNewswire - Tue Mar 25, 7:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of Integra Wound Matrix (Thin). Integra Wound Matrix (Thin) has received 510(k) clearance from the United States Food and Drug Administration (FDA) and expects to begin a full market release in the United States in April 2014. Integra's newest skin product will be featured at the American Burn Association Annual Meeting, March 25 - 28, 2014, in Boston, Massachusetts.
Use Options For A Chance To Buy IART At A 28% Discount
at The Street - Fri Mar 21, 10:57AM CDT
Looking back to 135 days ago, Integra LifeSciences Holdings Corp priced a 3,500,000 share secondary stock offering at $40.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go...
First Laminoplasty Implant at Integra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 5:00PM CDT
Integra LifeSciences announced the first human implantation of its Laminoplasty System in the U.S.
Integra LifeSciences Announces First Implantation of Integra(R) Laminoplasty System
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the first implantation of its Integra(R) Laminoplasty System, in the United States. The system, which is used to treat patients with ossification of the posterior longitudinal ligament, cervical myelopathy and degenerative spinal canal stenosis, was implanted by Douglas Orndorff, M.D., Orthopaedic Spine Surgeon at the Mercy Medical Center in Durango, Colorado.
Integra LifeSciences to Participate in the Barclays Global Healthcare Conference in March
GlobeNewswire - Mon Mar 03, 3:15PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conference next month:
Integra LifeSciences Receives FDA Clearance for Integra(R) Titanium Bone Wedges
GlobeNewswire - Thu Feb 27, 8:51AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the introduction of the Integra Titanium Bone Wedges, designed for internal fixation for bone fractures or osteotomies in the foot and ankle. The system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and will be featured at the American College of Foot and Ankle Surgeons (ACFAS) 72 Annual Scientific Conference, February 27 - March 2, 2014, in Orlando, Florida.
Integra LifeSciences Appoints Kenneth Burhop, Ph.D., as Corporate Vice President and Chief Scientific Officer
GlobeNewswire - Tue Feb 25, 7:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Kenneth Burhop has joined Integra as Corporate Vice President, Chief Scientific Officer. Dr. Burhop will be responsible for setting Integra's strategic scientific vision and roadmap, and will lead the Company's portfolio prioritization and management, and the scientific evaluation of corporate development and new product opportunities.
Integra LifeSciences Reports Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Feb 25, 5:00AM CST
Increases Fourth Quarter Revenues 3% to $221 Million
Integra LifeSciences to Participate in the 2014 Citi Global and RBC Capital Markets Healthcare Conferences in February
GlobeNewswire - Mon Feb 10, 8:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conferences next month:
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Integra LifeSciences Completes Acquisition of DuraSeal Product Lines From Covidien
GlobeNewswire - Wed Jan 15, 3:05PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed the acquisition of DuraSeal product lines from Covidien. Now, together with our DuraGen(R) family of grafts, Integra offers surgeons the largest portfolio of dural repair solutions.
Integra LifeSciences to Host Its Fourth Quarter 2013 Earnings Results Conference Call on February 25, 2014
GlobeNewswire - Mon Jan 13, 8:03AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its fourth quarter 2013 financial results on Tuesday, February 25, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
